Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
William P. Esler, David E. Cohen
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 362-377
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Genetic factors shaping the plasma lipidome and the relations to cardiometabolic risk in children and adolescents
Yun Huang, Sara Stinson, Malte Thodberg, et al.
EBioMedicine (2025) Vol. 112, pp. 105537-105537
Open Access | Times Cited: 1
SIRT1: Harnessing multiple pathways to hinder NAFLD
Cheng Tian, Rongrong Huang, Ming Xiang
Pharmacological Research (2024) Vol. 203, pp. 107155-107155
Open Access | Times Cited: 10
MetALD: Does it require a different therapeutic option?
George Marek, Harmeet Malhi
Hepatology (2024) Vol. 80, Iss. 6, pp. 1424-1440
Closed Access | Times Cited: 5
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
Monika Bhardwaj, Papiya Mitra Mazumder
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 5
Advancing de novo lipogenesis: Genetic and metabolic insights
Sean M. Hartig, Mark A. Herman
Cell Metabolism (2025) Vol. 37, Iss. 1, pp. 3-4
Closed Access
Hepatotoxicity of Three Common Liquid Crystal Monomers in Mus musculus: Differentiation of Actions Across Different Receptors and Pathways
Zhichao Zhang, Shengjie Yuan, Zhongchao Yang, et al.
Environmental Science & Technology (2025)
Closed Access
Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction–Associated Steatotic Liver Diseases: A Pathway to Precision Medicine
Xiang Zhang, Kyong‐Mi Chang, Jun Yu, et al.
Annual Review of Pathology Mechanisms of Disease (2025) Vol. 20, Iss. 1, pp. 375-403
Closed Access
An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences
Monika Bhardwaj, Papiya Mitra Mazumder
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Xiao Ma, Tengda Huang, Xi Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
Yu Wu, Pu Dong, Q H Wu, et al.
Clinical Pharmacology & Therapeutics (2025)
Closed Access
Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease
Daniela Ciobârcă, Adriana Florinela Cătoi, Laura Gavrilaș, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 279-279
Open Access
Integrative Metabolism in MASLD and MASH: Pathophysiology and Emerging Mechanisms
Gregory R. Steinberg, Celina M. Valvano, William De Nardo, et al.
Journal of Hepatology (2025)
Open Access
Absolute quantitative lipidomics reveals the disturbance of lipid metabolism induced by oral exposure of titanium dioxide nanoparticles
Nairui Yu, Jiaqi Shi, Ying Ma, et al.
NanoImpact (2025) Vol. 37, pp. 100554-100554
Closed Access
Positioning the liver at the centre of fructose-associated extrahepatic cancer
Thomas Marjot
Journal of Hepatology (2025)
Closed Access
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 4
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao Chen, Yang Zhou, Haiping Hao, et al.
Chinese Journal of Natural Medicines (2024) Vol. 22, Iss. 8, pp. 724-745
Closed Access | Times Cited: 4
Integrating liver endpoints in clinical trials of cardiovascular and kidney disease
Faı̈ez Zannad, Arun J. Sanyal, Javed Butler, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2423-2431
Closed Access | Times Cited: 3
Revisiting the concepts of de novo lipogenesis to understand the conversion of carbohydrates into fats: stop overvaluing and extrapolating the renowned phrase "fat burns in the flame of carbohydrate"
Heitor O. Santos, Nilson Penha‐Silva
Nutrition (2024) Vol. 130, pp. 112617-112617
Closed Access | Times Cited: 3
Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma
Takahiro Kodama, Tetsuo Takehara
Seminars in Liver Disease (2024) Vol. 44, Iss. 02, pp. 147-158
Open Access | Times Cited: 2
Lipidomics reveals the lipid-lowering and hepatoprotective effects of Celosia Semen on high-fat diet-induced NAFLD mice
Jin‐Quan Zhao, Zhou Qiqi, Ke Liu, et al.
Journal of Ethnopharmacology (2024) Vol. 337, pp. 118922-118922
Closed Access | Times Cited: 2
New Insights into AMPK, as a Potential Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatic Fibrosis
Hoon An, Yerin Jang, Jung-In Choi, et al.
Biomolecules & Therapeutics (2024)
Closed Access | Times Cited: 2
Topical rhubarb charcoal-crosslinked chitosan/silk fibroin sponge scaffold for the repair of diabetic ulcers improves hepatic lipid deposition in db/db mice via the AMPK signalling pathway
Qi Tan, Qifeng He, Ze Peng, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Common Bean Suppresses Hepatic Ceramide Metabolism in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease
Vanessa K. Fitzgerald, Tymofiy Lutsiv, John N. McGinley, et al.
Nutrients (2024) Vol. 16, Iss. 18, pp. 3196-3196
Open Access | Times Cited: 1
Body Composition and Progression of Biopsy‐Proven Non‐Alcoholic Fatty Liver Disease in Patients With Obesity
Qianyi Wan, Xingzhu Liu, Jinghao Xu, et al.
Journal of Cachexia Sarcopenia and Muscle (2024)
Open Access | Times Cited: 1
Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 9, pp. 1435-1436
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top